Quantum Biopharma MS Brain Imaging Study at Harvard's MGH: First Patient Milestone

Quantum BioPharma (NASDAQ: QNTM) has announced the first successful scan of a multiple sclerosis (MS) patient in a joint study with Massachusetts General Hospital (MGH). The study utilizes a novel PET tracer [18F]3F4AP to monitor myelin integrity and demyelination in MS patients. The scanning was performed using a new GE Signa PET-MR scanner, which allows simultaneous PET and MRI imaging, improving spatial and temporal coregistration while reducing patient scan time. This imaging technique could potentially serve as a biomarker to measure the effectiveness of drugs like Quantum's investigational MS drug Lucid-21-302. The PET tracer, developed by Dr. Pedro Brugarolas at MGH, has shown promising results in previous animal and human studies, demonstrating high sensitivity to demyelinated lesions and favorable pharmacokinetics.

https://www.stocktitan.net/news/QNTM/quantum-bio-pharma-announces-first-person-with-multiple-sclerosis-ms-31puykvfhd6f.html